Next Article in Journal
Implementation Science to Increase Adoption of Genomic Medicine: An Urgent Need
Previous Article in Journal
Is It Possible to Personalize the Diagnosis and Treatment of Breast Cancer during Pregnancy?
Article

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis

1
State Research Center of Dermatovenereology and Cosmetology, Korolenko St., 3, bldg 6, 107076 Moscow, Russia
2
Genotek Ltd., Nastavnicheskiipereulok 17/1, 105120 Moscow, Russia
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2021, 11(1), 20; https://doi.org/10.3390/jpm11010020
Received: 23 November 2020 / Revised: 18 December 2020 / Accepted: 25 December 2020 / Published: 29 December 2020
(This article belongs to the Section Pharmacogenetics)
One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectiveness of splitting patient cohorts based on clinical outcomes, which were assessed using the Psoriasis Area Severity Index (PASI). In total, 14 patients (41%) indicated having an advanced outcome with delta PASI 75 after treatment; 20 patients indicated having moderate or no effects. Genome variability was investigated using the Illumina Infinium Global Screening Array. Genome-wide analysis revealed apremilast therapy clinical outcome associations at three compact genome regions with undefined functions situated on chromosomes 2, 4, and 5, as well as on a single single-nucleotide polymorphism (SNP) on chromosome 23. Pre-selected SNP sets were associated with psoriasis vulgaris analysis, which was used to identify four SNP-associated targeted therapy efficiencies: IL1β (rs1143633), IL4 (IL13) (rs20541), IL23R (rs2201841), and TNFα (rs1800629) genes. Moreover, we showed that the use of the global polygenic risk score allowed for the prediction of onset psoriasis in Russians. Therefore, these results can serve as a starting point for creating a predictive model of apremilast therapy response in the targeted therapy of patients with psoriasis vulgaris. View Full-Text
Keywords: apremilast; psoriasis; genetic risk score; single-nucleotide polymorphism; clinical outcome apremilast; psoriasis; genetic risk score; single-nucleotide polymorphism; clinical outcome
Show Figures

Figure 1

MDPI and ACS Style

Verbenko, D.A.; Karamova, A.E.; Artamonova, O.G.; Deryabin, D.G.; Rakitko, A.; Chernitsov, A.; Krasnenko, A.; Elmuratov, A.; Solomka, V.S.; Kubanov, A.A. Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis. J. Pers. Med. 2021, 11, 20. https://doi.org/10.3390/jpm11010020

AMA Style

Verbenko DA, Karamova AE, Artamonova OG, Deryabin DG, Rakitko A, Chernitsov A, Krasnenko A, Elmuratov A, Solomka VS, Kubanov AA. Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis. Journal of Personalized Medicine. 2021; 11(1):20. https://doi.org/10.3390/jpm11010020

Chicago/Turabian Style

Verbenko, Dmitry A., Arfenya E. Karamova, Olga G. Artamonova, Dmitry G. Deryabin, Alexander Rakitko, Alexandr Chernitsov, Anna Krasnenko, Artem Elmuratov, Victoria S. Solomka, and Alexey A. Kubanov. 2021. "Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis" Journal of Personalized Medicine 11, no. 1: 20. https://doi.org/10.3390/jpm11010020

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop